Citigroup Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences (NASDAQ:NBIX) had its target price boosted by research analysts at Citigroup from $203.00 to $204.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s price objective points to a potential upside of 64.36% from the stock’s previous close.

Several other brokerages also recently weighed in on NBIX. BMO Capital Markets lowered their target price on Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating for the company in a research note on Thursday. JPMorgan Chase & Co. lowered their price objective on Neurocrine Biosciences from $179.00 to $177.00 and set an “overweight” rating for the company in a research note on Monday, January 12th. Canaccord Genuity Group lifted their price objective on Neurocrine Biosciences from $160.00 to $164.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Stifel Nicolaus upped their target price on Neurocrine Biosciences from $183.00 to $188.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Finally, Wedbush raised their price target on shares of Neurocrine Biosciences from $149.00 to $151.00 and gave the stock an “outperform” rating in a research report on Thursday. Sixteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $177.42.

Neurocrine Biosciences Stock Up 0.8%

NBIX opened at $124.12 on Thursday. The firm’s 50 day moving average is $140.14 and its 200-day moving average is $140.40. Neurocrine Biosciences has a 52-week low of $84.23 and a 52-week high of $160.18. The firm has a market capitalization of $12.38 billion, a P/E ratio of 26.64, a P/E/G ratio of 0.58 and a beta of 0.31.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing the consensus estimate of $2.36 by ($0.48). Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The firm had revenue of $805.50 million during the quarter, compared to analysts’ expectations of $804.21 million. During the same quarter last year, the company posted $1.69 earnings per share. Neurocrine Biosciences’s revenue for the quarter was up 28.3% compared to the same quarter last year. Equities analysts expect that Neurocrine Biosciences will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director George J. Morrow sold 15,000 shares of the company’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $143.37, for a total transaction of $2,150,550.00. Following the completion of the transaction, the director directly owned 7,068 shares in the company, valued at $1,013,339.16. This represents a 67.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kyle Gano sold 36,400 shares of the stock in a transaction on Friday, January 16th. The stock was sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares in the company, valued at $18,632,008.90. This represents a 20.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 61,966 shares of company stock worth $8,625,166. Company insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NBIX. Assetmark Inc. raised its stake in shares of Neurocrine Biosciences by 10.8% during the second quarter. Assetmark Inc. now owns 21,001 shares of the company’s stock valued at $2,640,000 after purchasing an additional 2,045 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in Neurocrine Biosciences by 87.9% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 125,162 shares of the company’s stock valued at $15,732,000 after buying an additional 58,562 shares in the last quarter. Saturn V Capital Management LP acquired a new position in Neurocrine Biosciences during the 2nd quarter valued at about $7,313,000. Capital Fund Management S.A. raised its position in shares of Neurocrine Biosciences by 15.9% during the 2nd quarter. Capital Fund Management S.A. now owns 203,628 shares of the company’s stock worth $25,594,000 after buying an additional 27,987 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB raised its position in shares of Neurocrine Biosciences by 66.1% during the 2nd quarter. Rhenman & Partners Asset Management AB now owns 149,217 shares of the company’s stock worth $18,755,000 after buying an additional 59,400 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Key Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Multiple analysts reiterated Buy/Outperform ratings and raised some price targets (Citigroup to $204, Bank of America reiterated Buy with a $190 target, Needham nudged to $185), signaling continued confidence in Ingrezza durability and pipeline upside. Analyst moves (Benzinga / TipRanks)
• Positive Sentiment: Q4 revenue grew strongly (~28% YoY to ~$805.5M) and company commentary highlighted Ingrezza sales growth and emerging uptake of pipeline assets — supports longer-term revenue trajectory. Earnings highlights (Yahoo)
• Neutral Sentiment: Deeper analysis pieces discuss growth beyond Ingrezza and portfolio opportunities that could drive medium-term upside but caution that 2026 may be less eventful. Useful for investors assessing longer-horizon thesis. Seeking Alpha: Growth Beyond Ingrezza
• Neutral Sentiment: Full Q4 earnings call transcripts and analyst note compilations are available for investors wanting primary commentary on guidance, expense cadence, and pipeline timelines. Review for detail before trading on headlines. Earnings transcripts & summaries
• Negative Sentiment: EPS missed expectations (Q4 EPS ~$1.88 vs. several consensus figures higher), and management issued cautious 2026 guidance — the combination sparked downside pressure and short-term uncertainty. Zacks: Q4 EPS lag
• Negative Sentiment: Some firms trimmed price targets or downgraded to Market Perform (BMO to $140; RBC and Wells Fargo trimmed targets though keeping Outperform/Overweight designations), reflecting more cautious near-term outlooks. Price target changes (Benzinga)
• Negative Sentiment: Market commentary highlights the stock’s sharp pullback after guidance and the EPS miss — articles explaining recent 8%+ decline underscore the sentiment risk if sales or cost pressures persist. AAII: Why NBIX is down

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.